Official UK visa sponsor profile for BRIDGEBIO UK LIMITED in London, including current register status, route details, and public company data.
BridgeBio UK Limited is a biotechnology company focused on the development of novel medicines targeting genetic diseases and cancers. Established in 2021, the company operates with a clear mission: to address unmet medical needs through innovative drug design. BridgeBio specializes in identifying and validating genetic drivers of disease, translating these insights into clinically viable therapies. The company’s core business involves preclinical research, drug discovery, and formulation development, with a particular emphasis on complex genetic conditions. BridgeBio’s team comprises experienced scientists and clinicians dedicated to advancing patient outcomes. They utilize a collaborative approach, partnering with leading research institutions and pharmaceutical companies. BridgeBio’s current status is active, and it is registered with the Financial Conduct Authority (FCA) under registration number 13623576. The company’s SIC codes include 46460 – Wholesale of pharmaceutical goods – reflecting its business model of distributing pharmaceutical products. BridgeBio’s international presence is currently being explored, and the company is actively seeking skilled workers to contribute to its growth. The company’s key focus is on the development of transformative medicines, with a strategic emphasis on complex genetic diseases and cancers.
Official UK visa sponsor profile for BRIDGEBIO UK LIMITED in London, including current register status, route details, and public company data.
BridgeBio UK Limited is a biotechnology company focused on the development of novel medicines targeting genetic diseases and cancers. Established in 2021, the company operates with a clear mission: to address unmet medical needs through innovative drug design. BridgeBio specializes in identifying and validating genetic drivers of disease, translating these insights into clinically viable therapies. The company’s core business involves preclinical research, drug discovery, and formulation development, with a particular emphasis on complex genetic conditions. BridgeBio’s team comprises experienced scientists and clinicians dedicated to advancing patient outcomes. They utilize a collaborative approach, partnering with leading research institutions and pharmaceutical companies. BridgeBio’s current status is active, and it is registered with the Financial Conduct Authority (FCA) under registration number 13623576. The company’s SIC codes include 46460 – Wholesale of pharmaceutical goods – reflecting its business model of distributing pharmaceutical products. BridgeBio’s international presence is currently being explored, and the company is actively seeking skilled workers to contribute to its growth. The company’s key focus is on the development of transformative medicines, with a strategic emphasis on complex genetic diseases and cancers.
Yes, BRIDGEBIO UK LIMITED is listed on the Home Office register of licensed sponsors. They are licensed for the Skilled Worker route.
BRIDGEBIO UK LIMITED is classified under: Wholesale of pharmaceutical goods.
Available visa routes:
* Costs are estimates based on 2026 rates. Actual costs may vary.
Ask AI about visa requirementsSponsor licenses change frequently. Always verify on the official GOV.UK register before applying.
Yes, BRIDGEBIO UK LIMITED is listed on the Home Office register of licensed sponsors. They are licensed for the Skilled Worker route.
BRIDGEBIO UK LIMITED is classified under: Wholesale of pharmaceutical goods.
Available visa routes:
* Costs are estimates based on 2026 rates. Actual costs may vary.
Ask AI about visa requirementsSponsor licenses change frequently. Always verify on the official GOV.UK register before applying.